Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
RHOLISTIQ (Kadmon Oceania Pty Ltd)
Product name
RHOLISTIQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
160 (255 working days)
Active ingredients
belumosudil mesilate
Registration type
NCE/NBE
Indication
RHOLISTIQ (film-coated tablet) is indicated for the treatment of patients with chronic graft-versus-host disease (chronic GVHD) aged 12 years and older who have an inadequate response to corticosteroids.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.